Sign in or Register
  |  

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Urinary Bladder Cancer

Fig.1 Urinary bladder cancer

Bladder cancer, as of 2015, affects around 3.4 million people with nearly 430,000 new cases a year. Age of onset is most commonly between 65 and 85. Males are more easily affected than females. Tobacco smoking is considered as the main known contributor to urinary bladder cancer. There are newer non-invasive urine bound markers available as aids in the diagnosis of bladder cancer, including human complement factor H-related protein, high-molecular-weight carcinoembryonic antigen, and nuclear matrix protein 22 (NMP22).